Elan Vote Puts Royalty's $8B Hostile Bid In Doubt
Elan’s shareholders approved a $200 million stock buyback at a special meeting Monday, the company said, though they voted down four other transactions up for approval. The final tally was not immediately available.
Royalty Pharma, which has been pursuing Elan since February, originally said it would...
To view the full article, register now.